Molecular imaging in the development of a novel treatment paradig.pdf (1.1 MB)
0/0

Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary.

Download (1.1 MB)
journal contribution
posted on 22.11.2019 by Monika A. Jarzabek, Kieron J. Sweeney, Rhys L. Evans, Andreas H. Jacobs, Roger Stupp, Donncha F. O'Brien, Mitchel S. Berger, Jochen HM Prehn, Annette Byrne

Current therapeutic strategies against glioblastoma (GBM) have failed to prevent disease progression and recurrence effectively. The part played by molecular imaging (MI) in the development of novel therapies has gained increasing traction in recent years. For the first time, using expertise from an integrated multidisciplinary group of authors, herein we present a comprehensive evaluation of state-of-the-art GBM imaging and explore how advances facilitate the emergence of new treatment options. We propose a novel next-generation treatment paradigm based on the targeting of multiple hallmarks of cancer evolution that will heavily rely on MI.

Funding

Funding is acknowledged within the context of the Irish National Biophotonics and Imaging Platform and the European Commission Framework Programme 7 AngioTox and AngioPredict initiatives

History

Comments

This article is also available at http://europepmc.org/abstract/MED/23792334

Published Citation

Jarzabek MA , Sweeney KJ , Evans RL , Jacobs AH , Stupp R , O'Brien D , Berger MS , Prehn JH , Byrne AT. Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. Drug Discovery Today. 2013;18(21-22):1052-1066.

Publication Date

01/11/2013

Publisher

Europe PMC

PubMed ID

23792334

Exports

Logo branding

Exports